David A. Siegel Lava Therapeutics Nv Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Lava Therapeutics Nv stock. As of the latest transaction made, Two Sigma Advisers, LP holds 16,700 shares of LVTX stock, worth $31,563. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,700Holding current value
$31,563% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LVTX
# of Institutions
26Shares Held
3.76MCall Options Held
28KPut Options Held
43.4K-
Redmile Group, LLC San Francisco, CA2.07MShares$3.92 Million0.27% of portfolio
-
Bruce & Co., Inc. Chicago, IL772KShares$1.46 Million1.27% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L3368KShares$694,7290.19% of portfolio
-
Walleye Capital LLC Plymouth, MN155KShares$292,3180.0% of portfolio
-
Alpha Wave Global, LP New York, NY108KShares$203,9420.2% of portfolio
About LAVA Therapeutics NV
- Ticker LVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,797,700
- Market Cap $48.8M
- Description
- LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...